Yemaachi Biotech is Africa's Cancer Research Company that is dedicated to revolutionizing cancer detection and cure strategies through cutting-edge immunogenomics, bioinformatics, and artificial intelligence. Their goal is to alleviate the economic burden of cancer on the African continent. Yemaachi Biotech offers a range of products and services designed to improve cancer care.

They have developed a Pan-African digital genomic and clinical knowledge base, in collaboration with clinical partners, to generate knowledge about cancer in African populations. This knowledge base enables them to optimize existing molecular diagnostic and prognostic tests for African populations and develop novel biomarkers for early cancer detection. In addition, Yemaachi Biotech partners with pharmaceutical and biotechnology companies to create innovative molecular diagnostics and therapeutics that are effective across different ethnicities and overcome the challenges of genetic variations.

They also provide affordable, fully accredited molecular cancer testing services, including NGS-based screening and prognostic testing. Yemaachi Biotech's mission is to redefine cancer diagnosis and treatment in Africa by promoting personalized medicine, engaging with local communities to raise awareness about cancer and the utility of genomic techniques in diagnosis and prognosis, and advancing medicine through sustainable biomedical research and partnerships